Suppr超能文献

局部前列腺癌患者(包括主动监测患者)的循环肿瘤细胞计数。

Circulating Tumor Cell Counts in Patients With Localized Prostate Cancer Including Those Under Active Surveillance.

机构信息

Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea.

Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

出版信息

In Vivo. 2019 Sep-Oct;33(5):1615-1620. doi: 10.21873/invivo.11645.

Abstract

AIM

To evaluate the clinical efficacy of a circulating tumor cell (CTC) test by comparison between healthy volunteers and patients with localized prostate cancer including those under active surveillance.

MATERIALS AND METHODS

CTC counts in peripheral blood were compared between patients with prostate cancer (n=45) and healthy volunteers (n=17). CTCs were identified based on the expression of epithelial cell adhesion molecule (EpCAM) and counted using a SMART BIOPSY™ SYSTEM.

RESULTS

The number of EpCAM+ cells was significantly higher in patients with cancer than in healthy volunteers. Among the low-risk patients (n=9), two had up-staging and six had up-grading. Among those up-staged, there was one case which was EpCAM Among those cases up-graded, three were EpCAM In those with stage T2 tumors, the presence of Gleason pattern 5 was positively correlated with EpCAM positivity (rho=0.59, p<0.001).

CONCLUSION

CTC counts in localized prostate cancer were associated with Gleason pattern 5. Active treatment should be considered for patients with low-risk disease during active surveillance who are found to have EpCAM+ CTCs because of a risk of up-staging and up-grading.

摘要

目的

通过比较局限性前列腺癌患者(包括主动监测患者)与健康志愿者,评估循环肿瘤细胞(CTC)检测的临床疗效。

材料与方法

对比了 45 例前列腺癌患者和 17 例健康志愿者外周血中的 CTC 计数。CTC 通过上皮细胞黏附分子(EpCAM)的表达进行鉴定,并使用 SMART BIOPSY™ SYSTEM 进行计数。

结果

癌症患者 EpCAM+细胞数量明显高于健康志愿者。在低危患者(n=9)中,2 例升期,6 例升级。在升期的病例中,有 1 例 EpCAM 阳性。在升级的病例中,有 3 例 EpCAM 阳性。在 T2 期肿瘤中,Gleason 模式 5 的存在与 EpCAM 阳性呈正相关(rho=0.59,p<0.001)。

结论

局限性前列腺癌的 CTC 计数与 Gleason 模式 5 相关。在主动监测中发现 EpCAM+CTC 的低危疾病患者,由于存在升期和升级的风险,应考虑进行积极治疗。

相似文献

3
Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer.
Urol Oncol. 2013 May;31(4):468-74. doi: 10.1016/j.urolonc.2011.03.007. Epub 2011 Apr 21.
4
Characterization of Urothelial Cancer Circulating Tumor Cells with a Novel Selection-Free Method.
Urology. 2018 May;115:82-86. doi: 10.1016/j.urology.2018.01.036. Epub 2018 Feb 9.
9
Epithelial cell adhesion molecule-positive circulating tumor cells as predictive biomarker in patients with prostate cancer.
Urology. 2013 Jun;81(6):1303-7. doi: 10.1016/j.urology.2012.10.041. Epub 2013 Apr 23.

引用本文的文献

1
Novel insights into biomarkers of progression in Desmoid tumor.
Front Oncol. 2023 Aug 3;13:1206800. doi: 10.3389/fonc.2023.1206800. eCollection 2023.
2
Utilization of Circulating Tumor Cells in the Management of Solid Tumors.
J Pers Med. 2023 Apr 20;13(4):694. doi: 10.3390/jpm13040694.
4
A Systematic Review of Circulating Tumor Cells Clinical Application in Prostate Cancer Diagnosis.
Cancers (Basel). 2022 Aug 4;14(15):3802. doi: 10.3390/cancers14153802.
5
Prognostic Implications of Portal Venous Circulating Tumor Cells in Resectable Pancreatic Cancer.
Biomedicines. 2022 May 31;10(6):1289. doi: 10.3390/biomedicines10061289.
6
Personal and Prognostic: Tissue and Liquid Biomarkers of Radiotherapeutic Response in Non-Small Cell Lung Cancer.
Semin Radiat Oncol. 2021 Apr;31(2):149-154. doi: 10.1016/j.semradonc.2020.11.002.

本文引用的文献

1
NCCN Guidelines Updates: Prostate Cancer and Prostate Cancer Early Detection.
J Natl Compr Canc Netw. 2018 May;16(5S):620-623. doi: 10.6004/jnccn.2018.0036.
2
Active surveillance review: contemporary selection criteria, follow-up, compliance and outcomes.
Transl Androl Urol. 2018 Apr;7(2):243-255. doi: 10.21037/tau.2018.03.02.
4
PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis.
Sci Rep. 2018 Mar 9;8(1):4254. doi: 10.1038/s41598-018-22594-1.
5
Establishment and Application of Prostate Cancer Circulating Tumor Cells in the Era of Precision Medicine.
Biomed Res Int. 2017;2017:7206307. doi: 10.1155/2017/7206307. Epub 2017 Nov 5.
6
Recent Changes in Prostate Cancer Screening Practices and Epidemiology.
J Urol. 2017 Dec;198(6):1230-1240. doi: 10.1016/j.juro.2017.05.074. Epub 2017 May 25.
7
PTEN loss and p27 loss differ among morphologic patterns of prostate cancer, including cribriform.
Hum Pathol. 2017 Jul;65:85-91. doi: 10.1016/j.humpath.2017.04.024. Epub 2017 May 10.
8
Microfluidic enrichment of circulating tumor cells in patients with clinically localized prostate cancer.
Urol Oncol. 2016 Nov;34(11):483.e9-483.e16. doi: 10.1016/j.urolonc.2016.06.004. Epub 2016 Sep 19.
9
Clinical and biological significance of circulating tumor cells in cancer.
Mol Oncol. 2016 Mar;10(3):408-17. doi: 10.1016/j.molonc.2016.01.010. Epub 2016 Feb 10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验